Overview

A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia

Status:
Completed
Trial end date:
2015-05-06
Target enrollment:
Participant gender:
Summary
A dose-escalation study to identify the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD), defined as the highest dose that can safely be given to a participant and establish the safest dose based on the highest tolerated dose for clinical testing.
Phase:
Phase 1
Details
Lead Sponsor:
MedImmune LLC
Collaborator:
Cambridge Antibody Technology
Treatments:
Antibodies
Antibodies, Blocking
Immunoglobulins
Immunotoxin HA22